Evaxion to Present Phase 2 EVX-01 Immunogenicity Data and Glioblastoma Neoantigen Findings
Evaxion will present two abstracts at the April 22 AACR Annual Meeting featuring new biomarker and immunogenicity data from its phase 2 melanoma vaccine EVX-01 trial combined with MSD’s anti-PD-1 therapy. The second abstract covers AI-Immunology identification of endogenous retrovirus-derived neoantigens for glioblastoma vaccines; Evaxion also joins the partnering event.
1. AACR Abstract Acceptance
Evaxion secured acceptance of two abstracts for presentation at the American Association for Cancer Research Annual Meeting on April 22, 2026, in San Diego, including slots in both the Clinical Research and Immunology sessions.
2. EVX-01 Phase 2 Trial Data
The first abstract, titled “AI-designed personalized neoantigen vaccine, EVX-01, induces durable de novo T-cell responses in advanced melanoma patients,” presents new biomarker and immunogenicity findings from the phase 2 trial combining individualized EVX-01 vaccines with MSD’s KEYTRUDA®; it will be shown as poster #7741 in the Clinical Research session.
3. Glioblastoma Neoantigen Strategy
The second abstract, “Endogenous retrovirus-derived neoantigens enable a personalized cancer vaccine strategy for glioblastoma,” details use of the AI-Immunology™ platform to identify ERV-derived neoantigens for personalized glioblastoma vaccines and will appear as poster #6975 in the Immunology session.
4. Industry Partnering Event
Ahead of the scientific sessions, Evaxion will participate in the AACR Oncology Industry Partnering event to engage potential collaborators and explore business and scientific partnership opportunities.